ArticlePeerJ2026
Multi-stage transcriptome analysis identifies hub genes and regulatory mechanisms driving cervical cancer progression.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of miR-21-5p and miR-21-3p regulated hub genes and drug repurposing targets in cervical cancer: an integrative computational analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer (CC) ranks as the fourth most prevalent cancer in women worldwide. While biomarkers exist, previous studies are often limited by public dataset heterogeneity, incomplete spectrum coverage, or lack of clinical validation. To address these limitations, this study aims to profile fresh tissues spanning the full continuum to systematically identify hub genes with dysregulated expression during malignant progression. Methods: This study collected cervical epithelial tissue from 10 patients each with low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL), and squamous cell carcinoma (SCC) for transcriptome sequencing. The differentially expressed genes (DEGs) analysis and Mfuzz clustering were employed to identify candidate genes showing monotonic expression trends. Candidate genes were prioritized using a protein-protein interaction (PPI) network with three centrality algorithms and validated in Gene Expression Omnibus to define hub genes. Subsequently, Gene Set Enrichment Analysis (GSEA), immune infiltration analysis, and regulatory network analyses were performed. Finally, hub gene expression was validated Results: A total of 1,654 DEGs (HSIL Conclusion: This study found the progressive upregulation of BUB1B, KIF14, and MELK across the LSIL-HSIL-SCC continuum, strengthening existing evidence of their association with cervical oncogenesis and highlighting their potential as candidate biomarkers for CC progression. However, the single-center design, limited sample size, and exploratory nature of the immune infiltration, regulatory network, and drug prediction analyses warrant cautious interpretation and underscore the need for further experimental validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.